TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00290420
Drug: Chloroquine profilaxis
Normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prevention:~Give a profilaxis with chloroquine once a week to prevent Plasmodium vivax malaria attacks and to prevent harmfull effect on birth outcomes
Study: NCT00004083
Drug: cisplatin liposomal
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00997815
Drug: Botulinum toxin A
Normalized name: Botulinum toxin A
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Concentration at 2 units per 0.1 of normal saline dilution
Study: NCT00997815
Drug: Normal saline injection
Normalized name: NS-2359
DrugBank: NS-2359 (DB05805)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Using normal saline 2.5 ml injected in control side
Study: NCT03593447
Drug: non-cirrhotic subjects. low TG-2349+ low DAG181+Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Group1: TG-2349 200 mg + DAG181 100 mg + Ribavirin 1000 mg or 1200 mg
Study: NCT03593447
Drug: non-cirrhotic subjects. high TG-2349+ high DAG181+Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Group2: TG-2349 400 mg + DAG181 200 mg + Ribavirin 1000 mg or 1200 mg
Study: NCT03593447
Drug: cirrhotic subjects. high TG-2349+ high DAG181+Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Group 5: TG-2349 400 mg + DAG181 200 mg + Ribavirin 1000 mg or 1200 mg_
Study: NCT01173926
Drug: insulin degludec
Normalized name: Insulin Degludec
DrugBank: Insulin degludec (DB09564)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Each trial participant will receive one single dose of each trial product in varying order (NN5401, NN1250 and insulin aspart) on 3 separate dosing visits. The trial products will be administered subcutaneously (under the skin).
Study: NCT01173926
Drug: insulin degludec/insulin aspart
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Each trial participant will receive one single dose of each trial product in varying order (NN5401, NN1250 and insulin aspart) on 3 separate dosing visits. The trial products will be administered subcutaneously (under the skin).
Study: NCT01173926
Drug: insulin aspart
Normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Each trial participant will receive one single dose of each trial product in varying order (NN5401, NN1250 and insulin aspart) on 3 separate dosing visits. The trial products will be administered subcutaneously (under the skin).
Study: NCT03849612
Drug: Insulin Lispro
Normalized name: Insulin Lispro
DrugBank: Insulin lispro (DB00046)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Individualized doses of insulin lispro administered via the AID system to maintain glycemic control, except during procedures designed to induce hyperglycemia and hypoglycemia.
Study: NCT03189433
Drug: Ryanodex (dantrolene sodium) for injectable suspension
Normalized name: dantrolene Injection [Ryanodex]
DrugBank: Dantrolene (DB01219)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ryanodex (dantrolene sodium) for injectable suspension, 250 mg/vial to be reconstituted in 5 mL of sterile water for injection to yield a 50 mg/mL suspension that will be administered as a rapid IV push of 2.5 mg/mL.
Study: NCT02520154
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT02520154
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given IV
Study: NCT02014454
Drug: Propranolol eye drops
DrugBank: Propranolol (DB00571)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All the enrolled preterm newborns will receive propranolol as ophthalmic solution (0,1%): 3 microdrops of 6 microliters (μL) propranolol solution (= 6 μg propranolol/microdrop) will be topically applied with a calibrated pipette, in each eye, three times daily (every 8 hours).The treatment will continue until the complete development of retinal vascularisation, but no more than 60 days.~The propranolol treatment will be always associated to the conventional approach adopted by the ETROP Cooperative Group.
Study: NCT01016015
Drug: Temsirolimus
Normalized name: Temsirolimus
DrugBank: Temsirolimus (DB06287)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given IV
Study: NCT00541489
Drug: Naproxcinod
Normalized name: Naproxcinod
DrugBank: Naproxcinod (DB06682)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 750 mg, bid
Study: NCT01624207
Drug: generic formulation of atorvastatin (Atorva®)
Normalized name: atorvastatin Oral Suspension [Atorvaliq]
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment with generic formulation of atorvastatin (Atorva®) once daily, for 8 weeks
Study: NCT01624207
Drug: branded formulation of atorvastatin (Lipitor®)
Normalized name: Genac brand of pseudoephedrine/triprolidine
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment with branded formulation of atorvastatin (Lipitor®)once daily, for 8 weeks
Study: NCT02819544
Drug: Sodium chloride administration
Normalized name: Sodium Chloride
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium chloride administration
Study: NCT02819544
Drug: Ropivacaine administration
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ropivacaine administration
Study: NCT02021318
Drug: Roxadustat
Normalized name: roxadustat
DrugBank: Roxadustat (DB04847)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Oral tablet.
Study: NCT02021318
Drug: Darbepoetin alfa
Normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subcutaneous or intravenous injection.
Study: NCT02569242
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT02569242
Drug: Docetaxel/Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00689052
Drug: pramipexole ER
Normalized name: pramipexole Extended Release Oral Tablet
DrugBank: Pramipexole (DB00413)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03306290
Drug: Serum dosage of antibiotic prophylaxis CEFOXITIN
Normalized name: combinations of different antibiotics
DrugBank: Cefoxitin (DB01331)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Three blood samples will be collected. These samples are specific for the research, and will be performed on the forearm opposite to the one used for Cefoxitin infusion.~1. Blood sample at the start of surgery (t0): at the end of the Cefoxitin infusion (\~30 min), 1 tube (5 ml) of blood will be withdrawn~2. Blood sample at half way surgery (t1): 1 tube (5 ml) of blood will be withdrawn (if applicable)~3. Blood sample at skin closure (t2): 1 tube (5 ml) of blood will be withdrawn
Study: NCT04227522
Drug: Rucaparib
Normalized name: Rucaparib
DrugBank: Rucaparib (DB12332)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: A starting dose of 600 mg Rucaparib is taken twice daily orally by the patients as maintenance after previous maintenance therapy (Bevacizumab) for a period of 12 to 15 months.
Study: NCT01740427
Drug: PD-0332991
Normalized name: dolutegravir
DrugBank: Dolutegravir (DB08930)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: PD-0332991, 125mg, orally once daily on Day 1 to Day 21 of every 28-day cycle followed by 7 days off treatment
Study: NCT01740427
Drug: Letrozole
Normalized name: Letrozole
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Letrozole, 2.5mg, orally once daily (continuously)
Study: NCT01217515
Drug: Diltiazem hydrochloride 4% cream
DrugBank: Diltiazem (DB00343)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3 times daily
Study: NCT01217515
Drug: Diltiazem hydrochloride 2% cream
DrugBank: Diltiazem (DB00343)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3 times daily
Study: NCT02614066
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered intravenously.
Study: NCT01678690
Drug: Gemcitabine HCl Oral Formulation
Normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Gemcitabine HCl Oral Formulation 80 mg/vial Subjects will be treated on Day 1 of the 7-day study treatment period
Study: NCT02466581
Drug: Sulphasalazine + Hydroxychloroquine OR Prednisolone
DrugBank: Chloroquine (DB00608)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methotrexate: 25mg/week. SSZ: 2 g/day. HCQ: 35 mg/kg/week (Finland and Denmark) Methotrexate: 25mg/week. Prednisolone 20 mg/day tapered in 9 weeks to 5 mg/day, discontinued after 9 months. (Sweden, Norway, and Iceland)
Study: NCT00362323
Drug: fenofibrate (F) + metformin (M) hydrochloride fixed combination
Normalized name: Metformin Hydrochloride
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: F80mg/M500mg - per os - twice a day during 24 weeks / or / F80mg/M850mg - per os - twice a day during 24 weeks /or / F54mg/M850mg - per os - three times a day during 24 weeks
Study: NCT00362323
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 500mg - per os - twice a day during 24 weeks /or / 850mg - per os - twice a day during 24 weeks /or / 850mg - per os - three times a day during 24 weeks
Study: NCT00538265
Drug: tacrolimus
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tacrolimus started at 0.50 mg/kg b.i.d. starting at D0, by nasogastric tube and then 1 to 2 hours before meals. The dose of tacrolimus will be adjusted as soon as possible to obtain trough concentrations of the product between 10 and 20 µg/L between D0 and 6 months and then between 8 and 15 µg/L after 6 months
Study: NCT00538265
Drug: tacrolimus, ATG
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: immunoprophylaxis allowing sparing of steroids in maintenance therapy combining induction therapy with 3 injections of antithymocyte globulins (ATG) (1.5 mg/kg/d at D0, D2 and D4) and tacrolimus at usual dosage.~In this group of patients, the first injection of ATG will be infused over a period of at least 6 hours and will be started as soon as vascular anastomosis has been completed. It will be preceded by an injection of 3 mg/kg/d methylprednisolone. The second injection of ATG at D2, post transplantation will also be infused over 6 hours and will be preceded by an injection of 1 mg/kg methylprednisolone, and then subsequently steroids will be excluded from the treatment. The third and last injection at D4 post transplantation will be administered over a 6-hour period but will not be preceded by steroids.~In this study arm, tacrolimus will be administered as in arm (A)
Study: NCT00538265
Drug: ATG+mycophénolate mofétil+tacrolimus
Normalized name: Mycophenolate Mofetil
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: immunoprophylaxis allowing sparing of steroids in maintenance therapy combined with mycophenolate mofetil, at an initial dosage of 2 grams a day, and then adjusted to safety and tolerability in such a way so as to maintain PMN ≥ 750/mm3, and platelet counts ≥ 30000/mm3.~In this study arm, the patients will receive the same doses of ATG and steroids (and according to the same methods) as in arm B. Tacrolimus started at 0.05 mg/kg b.i.d. starting at D0 by nasogastric tube and then 1 to 2 hours before meals. In this study arm, the tacrolimus dose will be reduced: targeted trough concentrations will be between 7 and 12 µg/L between D0 and 6 months and then between 3 et 7 µg/L after 6 months.
Study: NCT03542357
Drug: Calcitonin Gene Related Peptide
Normalized name: Calcitonin gene related peptide
DrugBank: Calcitonin gene-related peptide (DB06379)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CGRP is given both study days to induce headache. One day the headache is treated with placebo and the other day with sumatriptan
Study: NCT03542357
Drug: Sumatriptan 50 mg
Normalized name: sumatriptan 50 MG
DrugBank: Sumatriptan (DB00669)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CGRP is given both study days to induce headache. One day the headache is treated with placebo and the other day with sumatriptan
Study: NCT00968968
Drug: Lapatinib
Normalized name: Lapatinib
DrugBank: Lapatinib (DB01259)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Oral Lapatinib 1000 mg once daily. Lapatinib was a small molecule, reversible inhibitor targeting HER2 tyrosine kinase receptor.
Study: NCT00531817
Drug: Tocilizumab
Normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tocilizumab intravenously at a dose of 8 mg/kg over a 1-hour infusion, every 4 weeks, for a total of 6 infusions.
Study: NCT00053742
Drug: Modified Vaccinia Virus Ankara TBC-MVA
Normalized name: Modified vaccinia ankara
DrugBank: Modified vaccinia ankara (DB15483)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03624036
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered intravenously
Study: NCT03409458
Drug: PT-112
Normalized name: PT-2385
DrugBank: PT-2385 (DB16055)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The RP2D of PT-112 when used in combination with avelumab has been determined during dose escalation and is being confirmed in the NSCLC dose confirmation cohort.~For the NSCLC confirmation cohort, PT-112 will be administered at a dose of 360 mg/m2 on Days 1, 8 and 15.
Study: NCT01185366
Drug: Everolimus
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 10 mg by mouth once a day.
Study: NCT01185366
Drug: Sunitinib
Normalized name: Sunitinib
DrugBank: Sunitinib (DB01268)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 50 mg by mouth daily for 4 weeks on / 2 weeks off
Study: NCT02708706
Drug: hyaluronic acid (hyruan)
Normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (DB08818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2cc hyaluronic acid
Study: NCT03799120
Drug: Tamsulosin BID
DrugBank: Tamsulosin (DB00706)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: comparison of once daily versus twice daily tamsulosin
Study: NCT01691313
Drug: Vanoxerine
Normalized name: Vanoxerine
DrugBank: Vanoxerine (DB03701)
Approvals — FDA: no, EMA: no, PMDA: no
Description: single oral dose
Study: NCT01249443
Drug: vorinostat
Normalized name: Vorinostat
DrugBank: Vorinostat (DB02546)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT01249443
Drug: carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT01249443
Drug: paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given IV
Study: NCT02025036
Drug: Oxaliplatin(Aiheng)
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oxaliplatin(Aiheng)：65mg/m2，d1，8, 22, 29,I.V.
Study: NCT01390584
Drug: Bleomycin
Normalized name: Bleomycin
DrugBank: Bleomycin (DB00290)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV
Study: NCT01390584
Drug: Vinblastine
Normalized name: Vinblastine
DrugBank: Vinblastine (DB00570)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV
Study: NCT01390584
Drug: Dacarbazine
Normalized name: Dacarbazine
DrugBank: Dacarbazine (DB00851)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV
Study: NCT01390584
Drug: Etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV
Study: NCT01390584
Drug: Vincristine
Normalized name: Vincristine
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV
Study: NCT01390584
Drug: Procarbazine
Normalized name: Procarbazine
DrugBank: Procarbazine (DB01168)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PO
Study: NCT01390584
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PO
Study: NCT03782103
Drug: ChloraPrep
Normalized name: ChloraPrep
DrugBank: Chlorhexidine (DB00878)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Apply topically.
Study: NCT00231725
Drug: insulin lispro injection [rDNA origin] Low Mix
DrugBank: Insulin lispro (DB00046)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00362609
Drug: pantoprazole
Normalized name: Pantoprazole
DrugBank: Pantoprazole (DB00213)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02914223
Drug: Cenerimod
Normalized name: Cenerimod
DrugBank: Cenerimod (DB12705)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral formulation of cenerimod (2mg) containing 100 μCi (3.7 MBq) of 14C-radiolabeled cenerimod
Study: NCT00747071
Drug: Colostrum
Normalized name: Colostrum
DrugBank: Bos taurus colostrum (DB19249)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily administration of Colostrum derived antibodies against C. difficile.
Study: NCT00559351
Drug: neoadjuvant chemotherapy (cisplatin, 5-fluorouracil)
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 21-day combination systemic chemotherapy regimen consisted of a continuous infusion of cisplatin (20mg/m2/day) on days 1-5, 17-21 and 5-fluorouracil at 300mg/m2/day on days 1-21 followed by 3-phase transthoracic esophagectomy with 2-field extended lymphadenectomy after 3 week interval
Study: NCT04428593
Drug: Treamid 5 mg
Normalized name: Treamid
DrugBank: Treamid (DB16365)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The volunteers received the study drug once, and then continued daily intake for 14 days after a 6-day break.
Study: NCT04428593
Drug: Treamid 15 mg
Normalized name: Treamid
DrugBank: Treamid (DB16365)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The volunteers received the study drug once, and then continued daily intake for 14 days after a 6-day break.
Study: NCT04428593
Drug: Treamid 50 mg
Normalized name: Treamid
DrugBank: Treamid (DB16365)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The volunteers received the study drug once, and then continued daily intake for 14 days after a 6-day break.
Study: NCT02978508
Drug: Permethrin Cream, 5%
DrugBank: Permethrin (DB04930)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects on Test product will receive a maximum of two doses, 60 g each, during the study. The first dose will be applied on Day 1 in an outpatient setting, after the visit to the clinical site (preferably in the evening). The second dose will be applied on Day 14±2 only if retreatment is necessary.
Study: NCT02978508
Drug: Elimite
Normalized name: Elimite
DrugBank: Permethrin (DB04930)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects on RLD will receive a maximum of two doses, 60 g each, during the study. The first dose will be applied on Day 1 in an outpatient setting, after the visit to the clinical site (preferably in the evening). The second dose will be applied on Day 14±2 only if retreatment is necessary.
Study: NCT00295243
Drug: Topotecan
Normalized name: Topotecan
DrugBank: Topotecan (DB01030)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00562861
Drug: citalopram + mood stabilizer
DrugBank: Citalopram (DB00215)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Citalopram dose will be flexibly designed, beginning at 10 mg/d for at least one week, and the increased by 10 mg per week to a maximum of 50 mg/d. No target dose will be provided but rather clinicians will dose to clinical efficacy. Thus the study will provide clinicians data on the effective dose if it is positive. The dose will not be predetermined at static amounts.
Study: NCT02473263
Drug: Ceftriaxone
Normalized name: Ceftriaxone
DrugBank: Ceftriaxone (DB01212)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ceftriaxone 2g IV will be infused in the first 60 minutes, for non nosocomial severe septic syndrome
Study: NCT02473263
Drug: Piperacillin tazobactam
Normalized name: piperacillin / tazobactam
DrugBank: Piperacillin (DB00319)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Piperacillin/tazobactam 4g IV will be infused in the first 60 minutes, for nosocomial severe septic syndrome
Study: NCT00300495
Drug: Amiodarone
Normalized name: Amiodarone
DrugBank: Amiodarone (DB01118)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Perioperative orally administered
Study: NCT01348490
Drug: Ruxolitinib
Normalized name: Ruxolitinib
DrugBank: Ruxolitinib (DB08877)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ruxolitinib (INCB018424), 5 mg bid
Study: NCT02137681
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab was given intravenously at a dose of 375mg/m(2) weekly for 2 consecutive weeks (Day 1, 8) in 2 cycles arm; or 4 consecutive weeks (Day 1, 8, 15, 22) in standard 4 cycles arm
Study: NCT00257855
Drug: Lamotrigine
Normalized name: Lamotrigine
DrugBank: Lamotrigine (DB00555)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04007874
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E 400 IU oral capsules once daily for 3 months
Study: NCT00073047
Drug: Daclizumab
Normalized name: Daclizumab
DrugBank: Daclizumab (DB00111)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00667589
Drug: urea 40% cream
Normalized name: UREA 40% CREAM
DrugBank: Urea (DB03904)
Approvals — FDA: no, EMA: no, PMDA: no
Description: urea 40% cream applied twice per day to affected areas
Study: NCT00667589
Drug: fluocinonide 0.05% cream
Normalized name: FLUOCINONIDE 0.05% CREAM
DrugBank: Fluocinonide (DB01047)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: fluocinonide 0.05% cream applied twice per day to affected areas
Study: NCT00667589
Drug: tazarotene 0.1% cream
Normalized name: TAZAROTENE 0.1% CREAM,TOP
DrugBank: Tazarotene (DB00799)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: tazarotene 0.1% cream applied twice per day to affected areas
Study: NCT00002836
Drug: Carmustine
Normalized name: Carmustine
DrugBank: Carmustine (DB00262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Upon recovery of hematopoiesis patients then receive high by vein (IV) doses of CBT chemotherapy with CTX, carmustine, and thiotepa for 3 days
Study: NCT00002836
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: As part of CVP chemotherapy treatment by vein (IV) on days 1-3.
Study: NCT00002836
Drug: Etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: CVP chemotherapy treatment IV on days 1-3, with cyclophosphamide (CTX), etoposide, and cisplatin.
Study: NCT00002836
Drug: Thiotepa
Normalized name: Thiotepa
DrugBank: Thiotepa (DB04572)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Upon recovery of hematopoiesis receive high IV doses of CBT chemotherapy with CTX, carmustine, and thiotepa for 3 days.
Study: NCT02948075
Drug: Quisinostat
Normalized name: Quisinostat
DrugBank: Quisinostat (DB12985)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02948075
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT02948075
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes